Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial

著者: Sumanta K. Pal, Robert G. Uzzo, José A. Karam, Viraj A. Master, Frede Donskov, Cristina Suárez, Laurence Albigès, Brian I. Rini, Yoshihiko Tomita, Ariel Galapo Kann, Giuseppe Procopio, Francesco Massari, Matthew R. Zibelman, I. Antonyan, Mahrukh Huseni, Debasmita Basu, Bo Ci, William Leung, Omara Khan, Sarita Dubey, Axel Bex - The Lancet 2022 被引用: 230